Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer Adelina PlanggerBarbara RathGerhard Hamilton PRECLINICAL STUDIES Open access 01 October 2021 Pages: 215 - 223
Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma Julia SchnoellIsabella StaniszUlana Kotowski PRECLINICAL STUDIES Open access 06 October 2021 Pages: 224 - 231
Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma Xia YuanYi HeWei Wang PRECLINICAL STUDIES 11 October 2021 Pages: 232 - 244
FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells Chie IshikawaNaoki Mori PRECLINICAL STUDIES 26 October 2021 Pages: 245 - 254
Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model Hideki KashiwagiShinji KawabataMasahiko Wanibuchi PRECLINICAL STUDIES 24 November 2021 Pages: 255 - 264
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer Bo Mi KuJae Yeong HeoMyung-Ju Ahn PRECLINICAL STUDIES Open access 01 January 2022 Pages: 265 - 273
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo Gaojie SongChao ShangXiao Li Preclinical Studies Open access 04 January 2022 Pages: 274 - 289
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study Kyaw Z. TheinDaniel D. KarpAung Naing PHASE I STUDIES Open access 25 September 2021 Pages: 290 - 299
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors Elisabeth I. HeathAmy WeiseYasuo Urata PHASE I STUDIES 06 October 2021 Pages: 300 - 307
A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer Meijuan HuangYongmei LiuYou Lu PHASE I STUDIES Open access 01 November 2021 Pages: 308 - 313
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients Thomas YauPaul N. M. ChengChi Tao Ng PHASE I STUDIES 04 November 2021 Pages: 314 - 321
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer Corinne Maurice-DrorRonan Le MoigneKim N. Chi PHASE I STUDIES 29 November 2021 Pages: 322 - 329
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial Leiping WangJun CaoXichun Hu PHASE II STUDIES Open access 11 October 2021 Pages: 330 - 339
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer Xuetong RongHaiyi LiuYusheng Wang Phase II Studies Open access 08 January 2022 Pages: 340 - 348
Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial Daobin ZhouWei XuYue Lv Phase III Studies 15 January 2022 Pages: 349 - 360
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002 Motohiro TamiyaKei FujikawaSatoshi Teramukai PHASE III STUDIES 28 January 2022 Pages: 361 - 369
Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy Meng ZhangLijuan GaoXiaoyu Li REVIEW 27 November 2021 Pages: 370 - 388
Relapsing polychondritis after treatment with PD-1 blockade Tatsuya OgimotoHironori YoshidaToyohiro Hirai SHORT REPORT 25 September 2021 Pages: 389 - 391
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice Yuka HayakawaKaoru TsuchiyaNamiki Izumi SHORT REPORT 29 September 2021 Pages: 392 - 402
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer Ari NishimuraAkira OnoToshiaki Takahashi SHORT REPORT Open access 11 October 2021 Pages: 403 - 410
Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis Kosei DoshitaHirotsugu KenmotsuToshiaki Takahashi SHORT REPORT 30 October 2021 Pages: 411 - 419
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer Hisanaga NomuraDaiki TsujiToshikatsu Kawasaki Short Report 18 November 2021 Pages: 420 - 429
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study Satoshi IgawaTomoya FukuiKatsuhiko Naoki SHORT REPORT 22 November 2021 Pages: 430 - 437
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells Hugo Passos VicariJuan Luiz Coelho-SilvaJoão Agostinho Machado-Neto SHORT REPORT 27 November 2021 Pages: 438 - 452
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data Xiaowei ZhangFeng JinZhiguo Luo Short reports 03 November 2021 Pages: 453 - 460
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study Kyaw Zin TheinSarina A. Piha-PaulAung Naing Correction Open access 27 October 2021 Pages: 461 - 461
Correction to: Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma Nadire ÖzenverSara AbdelfatahThomas Efferth Correction Open access 27 October 2021 Pages: 462 - 462
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study Kyaw Z. TheinDaniel D. KarpAung Naing Correction Open access 03 November 2021 Pages: 463 - 463
Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer Ari NishimuraAkira OnoToshiaki Takahashi Author Correction 08 November 2021 Pages: 464 - 464